Patents Assigned to OncoCube Therapeutics LLC
  • Compositions and methods for treating cancer
    Patent number: 11986475
    Abstract: Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
    Type: Grant
    Filed: November 13, 2023
    Date of Patent: May 21, 2024
    Assignees: A2A Pharmaceuticals, Inc., OncoCube Therapeutics LLC
    Inventors: Chaemin Lim, Sridhar Vempati, Erden Banoglu, Burcu Caliskan, Ozgur Sahin
  • Highly potent TACC3 inhibitor as a novel anticancer drug candidate
    Patent number: 11622966
    Abstract: The present invention relates to a new inhibitor chemotype 3-(4-methoxyphenyl)-N-(2-morpholinopyrimidin-4-yl) isoxazol-5-amine (BO-264) targeting TACC3 protein with high potency as a mitotic blocker for the treatment of breast and potentially other cancers.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: April 11, 2023
    Assignees: A2A Pharmaceuticals, Inc., OncoCube Therapeutics LLC
    Inventors: Erden Banoglu, Burcu Caliskan, Ozgur Sahin, Deniz Lengerli, Ozge Akbulut
  • HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE
    Publication number: 20210220369
    Abstract: The present disclosure relates to 3-(4-methoxyphenyl)-N-(2-morpholinopyrimidin-4-yl) isoxazol-5-amine and methods of use thereof.
    Type: Application
    Filed: March 14, 2019
    Publication date: July 22, 2021
    Applicants: A2A Pharmaceuticals, Inc., OncoCube Therapeutics LLC
    Inventors: Erden Banoglu, Burcu Caliskan, Ozgur Sahin, Deniz Lengerli, Ozge Akbulut